|
![]() |
|||
|
||||
OverviewVulnerable plaque development is the result of a complex series of molecular and cellular events involving inflammation, apoptosis, rupture, and thrombosis. A detailed understanding of the mechanisms underlying the development of high-risk plaques, along with the ability to visualize and diagnose these vulnerable lesions, will lead to the effective management of acute coronary syndromes. High-Risk Atherosclerotic Plaques: Mechanisms, Imaging, Models, and Therapy brings together timely, in-depth reviews by renowned international cardiologists and scientists. Chapters cover the definition, structure, and cellular and molecular mechanisms of high risk plaque development, as well as animal models of vulnerable plaque, plaque imaging, and current and future therapies. Medical experts discuss intravascular ultrasound, optimal coherence tomography, magnetic resonance imaging, and coronary thermography. The final chapter reviews both current and future local and systematic strategies for the therapeutic management of vulnerable plaque. Exploring all aspects of this primary cause of acute coronary syndromes, this informative book updates our knowledge on the detection and treatment of vulnerable plaques. It is a valuable resource that can greatly advance the progress in treatment and prevention. Full Product DetailsAuthor: Levon Michael KhachigianPublisher: Taylor & Francis Ltd Imprint: CRC Press Weight: 0.420kg ISBN: 9780367454241ISBN 10: 0367454246 Pages: 224 Publication Date: 26 November 2019 Audience: Professional and scholarly , College/higher education , Professional & Vocational , Postgraduate, Research & Scholarly Format: Paperback Publisher's Status: Active Availability: In Print ![]() This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsReviewsAuthor InformationProfessor Levon Michael Khachigian (BSc(Hons), PhD, DSc) is a Principal Research Fellow of the National Health and Medical Research Council of Australia and Head of the Transcription and Gene Targeting Laboratory at The Centre for Vascular Research, University of New South Wales and Prince of Wales Hospital, Sydney. His research, encompassed in over 100 journal articles and book chapters, has greatly increased our understanding of the fundamental transcriptional mechanisms that led to the inappropriate expression of harmful genes in cells of the artery wall. It has also led to his generation of novel DNA-based drugs that block arterial renarrowing after balloon angioplasty in a variety of experimental models. More recently, he has been unravelling the mechanisms behind tumor growth control and other neovascular pathologies by inhibiting angiogenesis. Professor Khachigian has been a major contributor to the broader workings of science on matters of policy, advocacy, consultancy, peer-review, mentorship, and societal service. For example, he is National Executive Director and President-Elect of the Australian Society for Medical Research, and Immediate-Past President of the Australian Vascular Biology Society. He has served on numerous grant review, fellowship, and policy formulation panels for the National Health and Medical Research Council of Australia and the National Heart Foundation of Australia. He sits on the editorial boards of five international journals. Professor Khachigian has won many highly competitive awards for innovative research including the Commonwealth Health Minister’s Award for Excellence in Health and Medical Research, the Gottschalk Award from the Australian Academy of Science, Eureka Prize for Scientific Research from the Australian Museum, RT Hall Prize from the Cardiac Society of Australia and New Zealand, AMGEN Medical Researcher Award, Eppendorf Award for the Young Australian Researcher, Quantum Scientific Research Award, Young Tall Poppy Award, and numerous named research awards for research excellence from the Heart Foundation of Australia. Professor Khachigian received his BSc with first-class honors in biochemistry, and PhD in cell and molecular biology from the University of New South Wales, then studied transcriptional control in the Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School. In 2004, he was awarded a DSc in vascular pathobiology and translational research from the University of New South Wales. Tab Content 6Author Website:Countries AvailableAll regions |